Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01808976
Other study ID # R34MH100466
Secondary ID
Status Completed
Phase N/A
First received March 7, 2013
Last updated May 3, 2017
Start date April 2013
Est. completion date February 2017

Study information

Verified date May 2017
Source University of California, San Francisco
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Over two million people in the US download health apps onto their smartphones and tablets, with the intent of improving their quality of life. Despite widespread use of these apps, there is relatively little information regarding app user access (do users download health apps and use them more than once), app user engagement (do users follow the app protocols) and app impact on mood, cognition and daily functioning. Our long-term goal is to conduct a future randomized controlled trial investigating access, engagement and impact of two types of mental health apps, apps based on evidence-based therapeutic principles (i.e.: Problem Solving Therapy) and apps based on cognitive neuroscience principles of depression (i.e.: a cognitive training game called Evolution) and compare both to an information only app. Our intent is to conduct this study entirely on mobile devices, in order to investigate access, engagement, and impact in an ecologically valid manner. The purpose of this pilot study is to test the feasibility of conducting our future randomized controlled trial comparing three mobile mental health apps for the management of depressed mood, improvement of cognitive control, and improvement in activities of daily living in people aged 18 and older. Recruitment, consent, randomization, app use and outcome assessment will be conducted entirely on mobile devices. We will recruit 150 people through four different recruitment avenues to determine which avenue results in the most representative sample of our target population (people 18 and older who have symptoms of depression that are interfering with their quality of life). We will also determine the number we need to recruit to have a final sample of 150 people willing to be randomized between the 3 apps and complete an 12-week study of app impact on mood, cognition and function. This pilot will provide information on the completeness of data from a study conducted in this manner, and uncover any other challenges we may face by using mobile devices for data collection, and if we will find differential drop out between app type (e.g.: will more people stop using of the information only app prematurely?). Although we will not have sufficient statistical power to answer questions about comparative effectiveness between the apps, we plan to explore relationships between sample demographics, app use, and improvement in cognitive control on improvements in mood and function.


Description:

Participants will be recruited nationally from a variety of on-line sources. Participants will complete a breif on-line survey and then randomized to one of three mobile apps for depression. Participants are expected to use the apps for 4 weeks, complete daily ratings of mood, as well as complete 4 comprehensive assessments on their smart devices at weeks 1, 4, 8 and 12.


Recruitment information / eligibility

Status Completed
Enrollment 1000
Est. completion date February 2017
Est. primary completion date January 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- 18 years or older

- must own smart device (iPhone or ANDROID + iPAD)

- a total score of 5 or greater on the PHQ-9; OR a score of 2 or greater on at least one of the first two PHQ-9 items AND a score of 2 or greater on the 10th PHQ-9 item

- English speaking* (* as of 12/2016: this arm is closed)

- Spanish speaking (1st or second language)

Exclusion Criteria:

- below 18 years or older

- does not own a smart device

- a total score of less than 5 on the PHQ-9

- less than a score of 2 on the first two PHQ-9 items and less than 2 on the 10th PHQ-9 item

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Problem Solving Therapy
this is a mobile app that participants use to solve problems. It will guide participants through a stepwise process for identifying a means for creating action plans.
Behavioral:
Evolution
This is a therapeutic video game that targets the cognitive control network, associated with depression. Participants are expected to play the game daily for 20 minutes over 4 weeks.
Basic health push app
This is an app that send daily tips for improving your mood.

Locations

Country Name City State
United States Web-based; log onto www.brightenstudy.com/spa for details San Francisco California

Sponsors (1)

Lead Sponsor Collaborator
University of California, San Francisco

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Sheehan Disability Assessment Scale Assesses functional impairment in three inter-related domains; work/school, social and family life. Up to 3 weeks
Primary Patient Global Improvement Scale A 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. Up to 3 weeks
Primary Patient Health Questionnaire The PHQ-9 is the nine item depression scale of the Patient Health Questionnaire. The PHQ-9 is a powerful tool for assisting primary care clinicians in diagnosing depression as well as selecting and monitoring treatment. Up to 3 weeks
Primary Sheehan Disability Assessment Scale Assesses functional impairment in three inter-related domains; work/school, social and family life. Week 8
Primary Patient Global Improvement Scale A 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. Week 8
Primary Patient Health Questionnaire The PHQ-9 is the nine item depression scale of the Patient Health Questionnaire. The PHQ-9 is a powerful tool for assisting primary care clinicians in diagnosing depression as well as selecting and monitoring treatment. Week 8
Primary Sheehan Disability Assessment Scale Assesses functional impairment in three inter-related domains; work/school, social and family life. Week 12
Primary Patient Global Improvement Scale A 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. Week 12
Primary Patient Health Questionnaire The PHQ-9 is the nine item depression scale of the Patient Health Questionnaire. The PHQ-9 is a powerful tool for assisting primary care clinicians in diagnosing depression as well as selecting and monitoring treatment. Week 12
See also
  Status Clinical Trial Phase
Completed NCT04482296 - Effect of Zinc Supplementation on Depression in SSRI-treated Major Depressive Disorder Patients N/A
Recruiting NCT04071886 - Effect of Short-Term Mindfulness-Based Training For Major Depression Disorder: An Eye-Tracking Study N/A
Completed NCT04076644 - Maintenance Transcranial Magnetic Stimulation in Major Depressive Disorder N/A
Completed NCT05528315 - SAD/MAD of ABX-002-1902 Investigating the Safety, Pharmacokinetics/Pharmacodynamics of in Healthy Subjects Phase 1
Recruiting NCT05437588 - Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents N/A
Recruiting NCT06095778 - rTMS Therapy for Treatment-Resistant Depression With Different Targets Guided by pBFS N/A
Active, not recruiting NCT05657691 - Xanamem® in Adults With Major Depressive Disorder and Impaired Cognition (XanaCIDD) Phase 2
Completed NCT02013609 - Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment Phase 3
Completed NCT02339285 - Transcranial Alternating Current Stimulation for Major Depressive Disorder N/A
Recruiting NCT03971305 - A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With Systemic ALK(+) ALCL
Recruiting NCT05169346 - Neurofeedback to Treat Depression N/A
Completed NCT01344733 - A Non Interventional Study to Investigating the Ratio of Mis-diagnosed Bipolar Symptoms in Patient With Major Depressive Disorder (MDD) N/A
Completed NCT04268316 - Virtual Reality Behavioral Activation: An Intervention for Major Depressive Disorder N/A
Active, not recruiting NCT01557946 - Glutamatergic and GABAergic Mediators of Antidepressant Response in Major Depression Phase 2
Recruiting NCT01501812 - Evaluation of Generalization Paradigm Patterns Among Different Psychiatric Disorders N/A
Completed NCT04880460 - Effect of Magnesium Supplementation in Selective Serotonin Reuptake Inhibitors Treated Major Depressive Disorder Patients Phase 2
Completed NCT04226352 - Three Dosing Regimens of Dextromethorphan (DXM) Reportedly Used in Major Depressive Disorder Phase 1
Recruiting NCT03754712 - Effect of Vitamin D Administration Along With SSRIs in Patients With Major Depressive Disorder N/A
Recruiting NCT02669030 - A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia Phase 4
Completed NCT03994081 - Mechanism of Action of tACS for the Treatment of MDD N/A